Background Dipeptidyl peptidase-4 inhibitors (DPP-4is) improve glucose control in patients with type 2 diabetes mellitus (DM); however, only few studies were properly designed to evaluate their cardiovascular (CV) effects. The purpose of this study was to assess the impact of DPP-4i treatment on CV morbidity and mortality. Methods Randomized clinical trials enrolling more than 200 patients, comparing DPP-4 versus placebo or active treatments in patients with DM and reporting at least one event among all-cause and CV mortality, myocardial infarction (MI), stroke and new onset of heart failure (HF) were included in the analysis. Results Ninety-four trials enrolling 85,224 patients (median follow-up = 29 weeks) were included in the analysis. Compared to control, treatment with DPP-4i did not affect all-cause and CV mortality, as well as stroke, in the short and long terms (< and >= 29 weeks, respectively). DPP-4i reduced the risk of MI in the short (RR: 0.584 [95% CI: 0.361 to 0.943]; p = 0.028), but not in the long term. Additionally, long-term treatment with DPP-4 was associated with a 15.8% increased risk of HF (RR: 1.158 [CI: 1.011 to 1.326]; p = 0.034). No heterogeneity among studies or publication bias was detected. Conclusions DPP4is do not affect all cause-and CV-mortality and stroke in diabetic patients; the reduction in MI observed with short-term treatment does not persist in the long term. Long-term use of DPP-4i in diabetic patients is associated with increased risk of HF.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis / Savarese, G.; Perrone-Filardi, P.; D'Amore, C.; Vitale, C.; Trimarco, B.; Pani, L.; Rosano, G. M. C.. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - 181:(2015), pp. 239-244. [10.1016/j.ijcard.2014.12.017]

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis

Pani L.;
2015

Abstract

Background Dipeptidyl peptidase-4 inhibitors (DPP-4is) improve glucose control in patients with type 2 diabetes mellitus (DM); however, only few studies were properly designed to evaluate their cardiovascular (CV) effects. The purpose of this study was to assess the impact of DPP-4i treatment on CV morbidity and mortality. Methods Randomized clinical trials enrolling more than 200 patients, comparing DPP-4 versus placebo or active treatments in patients with DM and reporting at least one event among all-cause and CV mortality, myocardial infarction (MI), stroke and new onset of heart failure (HF) were included in the analysis. Results Ninety-four trials enrolling 85,224 patients (median follow-up = 29 weeks) were included in the analysis. Compared to control, treatment with DPP-4i did not affect all-cause and CV mortality, as well as stroke, in the short and long terms (< and >= 29 weeks, respectively). DPP-4i reduced the risk of MI in the short (RR: 0.584 [95% CI: 0.361 to 0.943]; p = 0.028), but not in the long term. Additionally, long-term treatment with DPP-4 was associated with a 15.8% increased risk of HF (RR: 1.158 [CI: 1.011 to 1.326]; p = 0.034). No heterogeneity among studies or publication bias was detected. Conclusions DPP4is do not affect all cause-and CV-mortality and stroke in diabetic patients; the reduction in MI observed with short-term treatment does not persist in the long term. Long-term use of DPP-4i in diabetic patients is associated with increased risk of HF.
181
239
244
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis / Savarese, G.; Perrone-Filardi, P.; D'Amore, C.; Vitale, C.; Trimarco, B.; Pani, L.; Rosano, G. M. C.. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - 181:(2015), pp. 239-244. [10.1016/j.ijcard.2014.12.017]
Savarese, G.; Perrone-Filardi, P.; D'Amore, C.; Vitale, C.; Trimarco, B.; Pani, L.; Rosano, G. M. C.
File in questo prodotto:
File Dimensione Formato  
VOR_Cardiovascular effects of dipeptidyl.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 373.23 kB
Formato Adobe PDF
373.23 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1211974
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 76
  • ???jsp.display-item.citation.isi??? 71
social impact